Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
Study of the safety and efficacy of AEB071 and EVEROLIMUS in patients with CD79-mutant or ABC
subtype Diffuse Large B-Cell Lymphoma.
The trial did not progress into Phase II due to the suboptimal tolerability of the
combination treatment of sotrastaurin and everolimus in the Phase Ib part of the study. There
were no serious safety concerns associated with this combination.